Prevalence, Costs and Consequences of “Manovra AIFA” for ICS-LABA Treatment in Patients with Asthma or COPD: A Real-Practice Analysis

Introduction The pharmaceutical respiratory market represents a growing expenditure for the National Healthcare System (NHS), mainly due to the increasing use of corticosteroid + long-acting β2 agonist (ICS-LABA) associations. Following a supplementary budget program (“manovra AIFA”, MA) in 2015, a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Global & regional health technology assessment (Online) 2016-11, Vol.3 (3), p.GRHTA.5000235
Hauptverfasser:	Bettiol, Alessandra, Bolcato, Jenny, Pirolo, Roberta, Franchin, Giulia, Deambrosis, Paola, Giusti, Pietro, Chinellato, Alessandro
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!